| SAGIMET BIOSCIENCES |
| USA |
| Gesundheit |
| US7867001049 / A3CPAM |
| 0O2 (Frankfurt) / SGMT (NASDAQ) |
| FRA:0O2, ETR:0O2, 0O2:GR, NASDAQ:SGMT |
| - |
| https://www.sagimet.com/ |
|
Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current prog..
>Volltext.. |
| 539.88 Mio. EUR |
| 330.79 Mio. EUR |
| - |
| -46.41 Mio. EUR |
| -41.52 Mio. EUR |
| -1.13 EUR |
| 1.71 Mio. EUR |
| 146.29 Mio. EUR |
| -36.79 Mio. EUR |
| 44.31 |
| - |
| 18.22% |
| - |
| - |
| - |
| - |
| SAGIMET |
| 30.09.26 |
|